The Diagnostic Performance of the Mindray System in Detecting CA125 and HE4 for Patients with Ovarian Cancer

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Sep 12

PMID 39262481

Authors

Pingfeng Feng

Tao Chen

Jorg Wischhusen

Colton Ladbury

Victor Manuel Vargas-Hernandez

Yufeng Xiong

Affiliations

Soon will be listed here.

Abstract

Background: Cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) are the most commonly used tumor biomarkers for ovarian cancer (OC) screening and diagnosis. The risk of ovarian malignancy algorithm (ROMA) score uses these markers, as detected by the Roche system, to predict the risk of OC. This study sought to assess the performance of the Mindray system in detecting CA125 and HE4 for ROMA score calculation in clinical settings.

Methods: Consecutive OC patients and patients with benign pelvic masses were screened and enrolled in this study. The CA125 and HE4 levels of these patients were measured using both the Mindray and Roche systems. The ROMA score for each patient was calculated. Diagnostic performance was evaluated using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve.

Results: The HE4 and CA125 levels were significantly higher in the patients with OC than the patients with benign ovarian masses. Both detection systems showed high efficiency in detecting ovarian cancer. For the premenopausal OC patients, the AUC values for the ROMA score, HE4, and CA125 were 0.866, 0.852, and 0.879, respectively, using the Roche system, and 0.911, 0.902, and 0.883, respectively, using the Mindray system. For the postmenopausal OC patients, the AUC values for the ROMA score, HE4, and CA125 were 0.962, 0.920, and 0.953, respectively, using Roche system, and 0.966, 0.924, and 0.959, respectively, using the Mindray system. The correlation analysis showed strong agreement between the two systems. Among the patients who experienced recurrence, we observed a significant increase in both HE4 and CA125 levels compared to baseline using the Mindray system.

Conclusions: The Mindray and Roche systems provide consistent results. The Mindray system can be used to detect HE4 and CA125 for ROMA score calculation.

References

Havrilesky L, Sanders G, Kulasingam S, Myers E . Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?. Gynecol Oncol. 2008; 111(2):179-87. DOI: 10.1016/j.ygyno.2008.07.006. View

Wang H, Liu P, Xu H, Dai H . Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model. Am J Transl Res. 2022; 13(12):14141-14148. PMC: 8748147. View

Lheureux S, Gourley C, Vergote I, Oza A . Epithelial ovarian cancer. Lancet. 2019; 393(10177):1240-1253. DOI: 10.1016/S0140-6736(18)32552-2. View

Sowamber R, Lukey A, Huntsman D, Hanley G . Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs. Curr Oncol. 2023; 30(12):10179-10194. PMC: 10742141. DOI: 10.3390/curroncol30120741. View

Wang Y, Lin W, Zhuang X, Wang X, He Y, Li L . Advances in artificial intelligence for the diagnosis and treatment of ovarian cancer (Review). Oncol Rep. 2024; 51(3). PMC: 10828921. DOI: 10.3892/or.2024.8705. View

Chen X, Zhou H, Chen R, He J, Wang Y, Huang L . Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clin Chim Acta. 2014; 440:57-63. DOI: 10.1016/j.cca.2014.11.013. View

The Lancet Digital Health . Digital transformation of ovarian cancer diagnosis and care. Lancet Digit Health. 2024; 6(3):e145. DOI: 10.1016/S2589-7500(24)00027-X. View

Di Donato V, Giannini A, DOria O, Schiavi M, DI Pinto A, Fischetti M . Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction. Ann Surg Oncol. 2020; 28(1):222-230. PMC: 7752869. DOI: 10.1245/s10434-020-08989-3. View

Benedetti Panici P, Giannini A, Fischetti M, Lecce F, Di Donato V . Lymphadenectomy in Ovarian Cancer: Is It Still Justified?. Curr Oncol Rep. 2020; 22(3):22. DOI: 10.1007/s11912-020-0883-2. View

10.

Bast Jr R, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J . New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005; 15 Suppl 3:274-81. DOI: 10.1111/j.1525-1438.2005.00441.x. View

11.

Yanaranop M, Anakrat V, Siricharoenthai S, Nakrangsee S, Thinkhamrop B . Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?. Gynecol Obstet Invest. 2016; 82(1):47-53. DOI: 10.1159/000446238. View

12.

Moore R, McMeekin D, Brown A, DiSilvestro P, Miller M, Allard W . A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2008; 112(1):40-6. PMC: 3594094. DOI: 10.1016/j.ygyno.2008.08.031. View

13.

Kim B, Park Y, Kim B, Ahn H, Lee K, Chung J . Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab Anal. 2018; 33(1):e22624. PMC: 6430343. DOI: 10.1002/jcla.22624. View

14.

Zapardiel I, Diestro M, Aletti G . Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol. 2013; 40(4):387-93. DOI: 10.1016/j.ejso.2013.11.028. View

15.

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019; 29(4):728-760. DOI: 10.1136/ijgc-2019-000308. View

16.

Sandri M, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S . Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2012; 128(2):233-8. DOI: 10.1016/j.ygyno.2012.11.026. View

17.

Urban N, McIntosh M, Andersen M, Karlan B . Ovarian cancer screening. Hematol Oncol Clin North Am. 2003; 17(4):989-1005, ix. DOI: 10.1016/s0889-8588(03)00063-7. View

18.

Li F, Tie R, Chang K, Wang F, Deng S, Lu W . Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer. 2012; 12:258. PMC: 3443004. DOI: 10.1186/1471-2407-12-258. View

19.

Ghaemmaghami F, Akhavan S . Is postoperative CA125 level in patients with epithelial ovarian cancer reliable to guess the optimality of surgery?. Eur J Gynaecol Oncol. 2011; 32(2):192-5. View

20.

Gu Z, He Y, Zhang Y, Chen M, Song K, Huang Y . Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer. J Transl Med. 2018; 16(1):114. PMC: 5930842. DOI: 10.1186/s12967-018-1489-4. View